114 related articles for article (PubMed ID: 6768491)
1. Release of norethisterone from a bioabsorbable implant in female bonnet monkeys (Macaca radiata).
Maitra A; Joshi UM; Kholkute SD; Munshi SR; Gupta GN; Tejuja S
Contraception; 1980 Feb; 21(2):165-73. PubMed ID: 6768491
[TBL] [Abstract][Full Text] [Related]
2. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
[TBL] [Abstract][Full Text] [Related]
3. Subdermal norethindrone pellets -- a method for contraception?
Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
[TBL] [Abstract][Full Text] [Related]
4. Serum norethindrone levels and menstrual pattern after the use of norethindrone implants in rhesus monkeys.
Jha P; Murugesan K; Farooq A
Contraception; 1995 Feb; 51(2):117-20. PubMed ID: 7750289
[TBL] [Abstract][Full Text] [Related]
5. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
Laumas V; Jain AK; Jha P; Rahman SA; Kumar D; Malik BK; Sarkar NN; Takkar D; Hingorani V; Laumas KR
Contraception; 1981 Feb; 23(2):211-25. PubMed ID: 6786828
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable norethindrone (NET:cholesterol) contraceptive implants: phase II-A: a clinical study in women.
Singh M; Saxena BB; Raghubanshi RS; Ledger WJ; Harman SM; Leonard RJ
Contraception; 1997 Jan; 55(1):23-33. PubMed ID: 9013058
[TBL] [Abstract][Full Text] [Related]
7. Effect of intranasal administration of norethisterone and progesterone on pituitary and gonadal function in adult male and female bonnet monkeys (Macaca radiata).
Moudgal RN; Jagannadha Rao A; Murthy GS; Neelakanta R; Banavar SR; Kotagi SG; Anand Kumar TC
Fertil Steril; 1985 Jul; 44(1):120-4. PubMed ID: 4007187
[TBL] [Abstract][Full Text] [Related]
8. Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
Raymond EG; Singh M; Archer DF; Saxena BB; Baker J; Cole D
Fertil Steril; 1996 Dec; 66(6):954-61. PubMed ID: 8941061
[TBL] [Abstract][Full Text] [Related]
9. Norethisterone contraceptive microspheres.
Rivera R; Alvarado G; Flores C; Aldaba S; Hernandez A
J Steroid Biochem; 1987; 27(4-6):1003-7. PubMed ID: 3695501
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of norethindrone and menstrual pattern after insertion of norethindrone acetate implants in rhesus monkeys.
Jha P; Murugesan K; Farooq A
Contraception; 1991 Sep; 44(3):327-34. PubMed ID: 1764947
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
Victor A; Lithell H; Selinus I; Vessby B
Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous bioabsorbable pellets of norethindrone for contraception in women: Phase I. Clinical study.
Gupta GN; Saxena BB; Landesman R; Ledger WJ
Fertil Steril; 1984 May; 41(5):726-31. PubMed ID: 6714449
[TBL] [Abstract][Full Text] [Related]
13. Contraceptive efficacy of bioabsorbable pellets of norethindrone (NET) as subcutaneous implants: phase II clinical study.
Singh M; Saxena BB; Landesman R; Ledger WJ
Adv Contracept; 1985 Jun; 1(2):131-49. PubMed ID: 3842214
[TBL] [Abstract][Full Text] [Related]
14. The effect of injectable norethisterone oenanthate on ovarian hormones in Thai women.
Werawatgoompa S; Vaivanijkul B; Leepipatpaiboon S; Channiyom K; Virutamasen P; Dusitsin N
Contraception; 1980 Mar; 21(3):299-309. PubMed ID: 7389353
[TBL] [Abstract][Full Text] [Related]
15. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
16. The use of biodegradable norethisterone implants as a 6-month contraceptive system.
Rivera R; Gaitan JR; Ortega M; Flores C; Hernandez A
Fertil Steril; 1984 Aug; 42(2):228-32. PubMed ID: 6745456
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of injectable biodegradable contraceptive system.
Beck LR; Ramos RA; Flowers CE; Lopez GZ; Lewis DH; Cowsar DR
Am J Obstet Gynecol; 1981 Aug; 140(7):799-806. PubMed ID: 7020421
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of norethisterone following its oral administration and by spraying it nasally or sublingually to male bonnet monkeys.
Puri CP; Vajifdar BS; Nayak VG; Dhanasekaran K; Pongubala JM; Hamied YK; Anand Kumar TC
Contraception; 1987 Apr; 35(4):381-8. PubMed ID: 3621938
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of norethindrone and effect upon ovarian function during treatment with silastic implants containing norethindrone.
Odlind V; Weiner E; Johansson ED
Contraception; 1979 Feb; 19(2):197-206. PubMed ID: 428235
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of two contraceptive preparations. Norethisterone enanthate (NEN) and norethisterone acetate (NET).
Andino N
Contraception; 1981 Feb; 23(2):141-55. PubMed ID: 6786825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
